$30.42
1.27% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US8753722037
Symbol
TNDM

Tandem Diabetes Care, Inc. Stock price

$30.42
-0.93 2.97% 1M
-21.31 41.19% 6M
+0.84 2.84% YTD
+10.95 56.24% 1Y
-102.46 77.11% 3Y
-40.77 57.27% 5Y
-111.98 78.64% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.39 1.27%
ISIN
US8753722037
Symbol
TNDM
Sector

Key metrics

Market capitalization $2.00b
Enterprise Value $2.00b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.34
P/S ratio (TTM) P/S ratio 2.34
P/B ratio (TTM) P/B ratio 8.40
Revenue growth (TTM) Revenue growth 10.75%
Revenue (TTM) Revenue $854.35m
EBIT (operating result TTM) EBIT $-133.61m
Free Cash Flow (TTM) Free Cash Flow $-15.07m
Cash position $473.31m
EPS (TTM) EPS $-1.94
P/E forward negative
P/S forward 2.20
EV/Sales forward 2.20
Short interest 19.79%
Show more

Is Tandem Diabetes Care, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Tandem Diabetes Care, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

16x Buy
70%
6x Hold
26%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from Tandem Diabetes Care, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
854 854
11% 11%
100%
- Direct Costs 429 429
12% 12%
50%
425 425
9% 9%
50%
- Selling and Administrative Expenses 353 353
1% 1%
41%
- Research and Development Expense 189 189
16% 16%
22%
-117 -117
4% 4%
-14%
- Depreciation and Amortization 16 16
7% 7%
2%
EBIT (Operating Income) EBIT -134 -134
3% 3%
-16%
Net Profit -127 -127
39% 39%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Tandem Diabetes Care, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tandem Diabetes Care, Inc. Stock News

Neutral
Business Wire
5 days ago
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024 at 8:00am Eastern Time (5:00am Pacific Time), and Citi's 2024 Global Healthcare Conferen...
Neutral
Seeking Alpha
19 days ago
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Neutral
Business Wire
20 days ago
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales guidance for the year ending December 31, 2024. Third Quarter 2024 Highlights Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023;...
More Tandem Diabetes Care, Inc. News

Company Profile

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Head office United States
CEO John Sheridan
Employees 2,400
Founded 2006
Website www.tandemdiabetes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today